The price of hesitation – POLITICO

European governments navigate an ever more competitive global landscape, stagnating productivity and competing demands on budgets. We have successfully faced and solved many challenges in the past, but this situation is different: the choices we make today will shape our health​ ​care systems and patient care, and these choices will dictate Europe’s economic performance and global relevance for decades to come.

For those of us in the life sciences, these aren’t just macroeconomic trends — they are the pulse of a system that determines how quickly a breakthrough reaches a patient. It is a high-stakes environment where policies on health​ ​care and innovation carry urgent human and economic consequences. When a medicine has the power to treat or potentially cure, neither innovators nor policymakers want to drag their heels, because no person requiring health​ ​care can afford the luxury of delay.

The true economic burden of health​ ​care isn’t financing health innovation, but the cost of failing to do so.

Europe’s challenge is clear: we must better align our industrial strength in life science with public health goals, ensuring innovation reaches both patients and economies faster. The question is no longer what Europe ​wants​ to be — it is where Europe ​chooses​ to invest to remain a global player.